FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer

June 12, 2026 4:10 PM

The U.S. Food and Drug Administration approved Merck's (NYSE: MRK) KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found